Two of the world’s largest pharmaceutical conglomerates have become embroiled in an escalating takeover battle for Metsera, an emerging biotech on the verge of breakthroughs in weight-loss drug innovation. Novo
Weightloss2- Page
41Articles
The powerful Novo Nordisk Foundation, the largest shareholder in pharmaceutical giant Novo Nordisk, has executed a dramatic boardroom takeover after a sharp disagreement about the company’s strategic direction. The move,
Weight loss injections have rapidly transformed the British approach to tackling obesity, with an extraordinary surge in private usage. Latest data suggests that 2.5 million adults in the UK—one in
Denmark’s pharmaceutical powerhouse Novo Nordisk is set to axe 9000 jobs, marking one of the most substantial workforce reductions in its history, as the company battles a steeply declining share
Over a million people in the United Kingdom who use weight-loss jabs such as Mounjaro Ozempic and Wegovy may be risking their travel and health insurance due to confusion over
The United Kingdom stands on the threshold of a radical transformation in obesity treatment, as Eli Lilly prepares to introduce a daily weight-loss pill, Orforglipron, in 2026, once regulatory approval
Eli Lilly, the US manufacturer of the weight management injection Mounjaro, has announced a new discount for private pharmacies in the UK. The move follows widespread concern after the company
Eli Lilly, one of the world’s largest pharmaceutical companies, has temporarily halted orders of its highly sought-after weight-loss injection, Mounjaro, to the UK. This move comes as the market braces
Eli Lilly, the pharmaceutical giant behind the popular weight loss injection Mounjaro, has announced a substantial price hike for the medication due to take effect in the UK from September.
Weight loss medications, specifically GLP1 agonists like Ozempic Wegovy and Mounjaro, are redefining the landscape of healthcare in Britain, with new research signposting not only longer lives for millions but
A leading biopharmaceutical business saw its shares tumble by almost 40 per cent after results from a trial of its much-anticipated weight loss pill failed to meet market expectations. Viking
The UK market for prescription weight loss injections has witnessed dramatic upheaval, prompted by a sharp price increase for Mounjaro, currently the nation’s most widely used weight loss jab. From
Shares in Novo Nordisk climbed over five per cent on the Copenhagen exchange after the Danish pharmaceuticals firm received crucial approval from the United States Food and Drug Administration for
A major rise in the cost of Mounjaro is set to impact more than a million weight loss patients across Britain next month amid an international dispute over medicine prices.
A new oral medication weight loss, orforglipron, has shown promising results in a landmark trial, marking a significant step for obesity treatment in the UK. Developed by Eli Lilly, orforglipron
WeightWatchers is embarking on a transformative journey following a significant debt restructuring, positioning itself to compete in the evolving landscape of weight management solutions. The company, which recently emerged from
